6-K 1 d159333d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Dated May 27, 2016

Commission File Number 001-35428

 

 

PRIMA BIOMED LTD

(Exact Name as Specified in its Charter)

 

 

N/A

(Translation of Registrant’s Name)

Level 12, 95 Pitt Street

Sydney, 2000 New South Wales, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 27, 2016

 

PRIMA BIOMED LTD
By:  

/s/ Marc Voigt

Name:   Marc Voigt
Title:   Chief Executive Officer

 

2

EXHIBIT INDEX

 

Exhibit

   

Description of Exhibit

99.1    Prima BioMed Ltd Interim Financial Report for the Half-Year Ended 31 December 2015
99.2    Prima BioMed Ltd Management’s Discussion & Analysis for the Half-Year Ended 31 December 2015
99.3    Immutep S.A.S. Financial Statements for the Period Ended December 12, 2014
99.4    Unaudited Pro Forma Condensed Combined Financial Information for the 12 Months Ended June 30, 2015 (relating to the Acquisition of Immutep S.A.S. by Prima BioMed Ltd)

 

3